Výsledky vyhledávání - "Susan McCanna"

Akademický článek

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Autor: Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang

Publikováno v: Breast Cancer Research, Vol 22, Iss 1, Pp 1-9 (2020)

Abstract Background Cancer stem cells (CSCs) are purported to be responsible for tumor initiation, treatment resistance, disease recurrence, and metastasis. CXCR1, one of the receptors for CXCL8, was identified on breast cancer (BC) CSCs. Reparixin,

Externí odkaz: https://doaj.org/article/ac829d2cdaf14d13a5d03603e1a74bd8

Zobrazit plný text záznamu

Akademický článek

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Autor: Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang

Publikováno v: Breast Cancer Research, Vol 22, Iss 1, Pp 1-1 (2020)

An amendment to this paper has been published and can be accessed via the original article.

Externí odkaz: https://doaj.org/article/afe8b27d2fe7432cb7808d7f67f3db50

Zobrazit plný text záznamu

Data from Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer

Autor: Max Wicha, Giraldo Kato, Raymond P. Perez, James M. Reuben, Susan McCanna, Pier Adelchi Ruffini, Massimo Cristofanilli, Lori J. Goldstein, Anne F. Schott

Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable receptor selectively expressed by breast cancer stem cells (BCSCs). Reparixin is an investigational allosteric inhibitor of chemokine receptors 1 and 2 (CXCR1/2), and demonstrates a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57e5bb1502f1448f915084deeea30ad1
https://doi.org/10.1158/1078-0432.c.6526848.v1

Zobrazit plný text záznamu

Abstract P3-11-07: A randomized phase II trial of reparixin, a CXCR1 inhibitor, in combination with paclitaxel in the treatment of mTNBC

Autor: Isaura Fernandez-Perez, Pier Adelchi Ruffini, Giuseppe Viale, Beth Butler, Jenny C. Chang, Mauro Mansutti, Christelle Levy, Susan McCanna, Anne F. Schott, Stephanie Henry, Lori J. Goldstein, Guiseppe Viale, Max S. Wicha

Publikováno v: Cancer Research. 80:P3-11

Background: CXCR1, one of the receptors for CXCL8, has been identified as a druggable target on breast cancer Cancer Stem Cells (CSC): In a phase 1b study, the combination of reparixin (R), an investigational oral inhibitor of CXCR1, and weekly pacli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18485935185e9b4a9506e02bfb84263c
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-07

Zobrazit plný text záznamu

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Autor: Beth Butler, Linda K. Han, Raymond P. Perez, Denise A. Yardley, Hui Gao, Pier Adelchi Ruffini, Jenny C. Chang, Lori J. Goldstein, Roberto R. Rosato, Susan McCanna, James M. Reuben, Yi Liu

Publikováno v: Breast Cancer Research : BCR
Breast Cancer Research, Vol 22, Iss 1, Pp 1-1 (2020)

Background Cancer stem cells (CSCs) are purported to be responsible for tumor initiation, treatment resistance, disease recurrence, and metastasis. CXCR1, one of the receptors for CXCL8, was identified on breast cancer (BC) CSCs. Reparixin, an invest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01e448bee451153d2105ddb5d83cacb4
http://europepmc.org/articles/PMC7238734

Zobrazit plný text záznamu

Abstract OT1-03-07: A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for triple-negative breast cancer (fRida)

Autor: Susan McCanna, Massimo Cristofanilli, Jenny C. Chang, Pier Adelchi Ruffini, Wicha, Lori J. Goldstein, Anne F. Schott

Publikováno v: Cancer Research. 76:OT1-03

Background: Breast cancer stem cells (BCSC) have the ability to self renew and generate the full range of cells that make up a bulk tumor. Experimental models and retrospective clinical observations point to BCSC as responsible for tumor recurrence a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::50ed766f0f37d420431f27c310a7c4d7
https://doi.org/10.1158/1538-7445.sabcs15-ot1-03-07

Zobrazit plný text záznamu

Abstract OT2-6-03: A single arm, preoperative, pilot study to evaluate the safety and biological effects of orally administered reparixin in early breast cancer patients who are candidates for surgery

Autor: JM Reuben, Landis, Jenny C. Chang, Pier Adelchi Ruffini, Lori J. Goldstein, M Cristofanilli, C Vito, Susan McCanna, Raymond P. Perez, J Sparano

Publikováno v: Cancer Research. 73:OT2-6

Background. Experimental models and retrospective clinical observations point to Cancer Stem Cells (CSC) as responsible for tumor initiation, treatment resistance, disease recurrence and metastasis. CXCR1, one of the receptors for CXCL8, was identifi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a711c320e416398f339680045e19ede4
https://doi.org/10.1158/0008-5472.sabcs13-ot2-6-03

Zobrazit plný text záznamu

Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer

Autor: Giraldo Kato, Anne F. Schott, Max S. Wicha, Pier Adelchi Ruffini, James M. Reuben, Lori J. Goldstein, Massimo Cristofanilli, Susan McCanna, Raymond P. Perez

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 23(18)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2044cde4160cc00ebe9431f244040663
https://pubmed.ncbi.nlm.nih.gov/28539464

Zobrazit plný text záznamu

Abstract CT057: A single-arm, preoperative, pilot study to evaluate the safety and biological effects of orally administered reparixin in early breast cancer patients who are candidates for surgery

Autor: Lori J. Goldstein, Raymond P. Perez, Denise A. Yardley, Linda K. Han, James M. Reuben, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Jenny C. Chang

Publikováno v: Cancer Research. 76:CT057-CT057

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::919a1bab9e69b21c884a30cebf58a266
https://doi.org/10.1158/1538-7445.am2016-ct057

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání